Disease Info Card

Malignant Fibrous Histiocytoma

Information about Malignant Fibrous Histiocytoma: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Malignant Fibrous Histiocytoma

Most recent studies have shown that Malignant Fibrous Histiocytoma shares some biological mechanisms with bone-neoplasms, carcinoma, chondrosarcoma, fibrosarcoma, histiocytoma, histiocytoma-benign-fibrous, leiomyosarcoma, liposarcoma, lung-neoplasms, malignant-neoplasms, malignant-paraganglionic-neoplasm, neoplasm-metastasis, neoplasm-recurrence-local, neoplasms, osteosarcoma, rhabdomyosarcoma, sarcoma, skin-neoplasms, soft-tissue-neoplasms, synovial-sarcoma.

Among the many pathways, these few ones have gauged particular interests from scientists studying Malignant Fibrous Histiocytoma, and have been seen in publications frequently: Angiogenesis, Cell Adhesion, Cell Cycle, Cell Death, Cell Differentiation, Cell Growth, Cell Proliferation, Coagulation, Dedifferentiation, Localization, Metaphase, Methylation, Mitosis, Oncogenesis, Pathogenesis, Phagocytosis, Reverse Transcription, Secretion, Wound Healing

Quite a number of genes have been found to play important roles in Malignant Fibrous Histiocytoma, such as CD34, CD68, CTLA4, DES, HLA-DQA1, KIT, LYZ, MB, MDM2, MUC1, NOD2, S100A1, S100B, SERPINA1, SERPINA3, STS, TP53, VIM. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.